CClinicalTrials.gg
RecruitingNCT05406830Updated Mar 12, 2024

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

An interventional study of verum acupuncture and health education in Asymptomatic Hyperuricemia, sponsored by Lingling Yu (103250). Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Lingling Yu (103250) · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.

Read the detailed description

This is a multicentre, stratified, randomized, sham-controlled clinical trial. 180 eligible participants will be randomly allocated into verum acupuncture group or sham acupuncture group, in a 1:1 ratio. The verum acupuncture group will receive 16 sessions of manual acupuncture treatments over an eight-week period, while the sham acupuncture group will receive sham acupuncture treatments with non-penetrating needling. Health education will be provided to participants in the two groups. The primary outcomes will be the changes in the mean levels of serum uric acid 8 weeks after randomization. The secondary outcomes will be the changes in the mean levels of serum uric acid 4, 12, 16, and 20 weeks after randomization. Other secondary outcomes included effective rates, the proportion of patients with acute gouty arthritis, changes in body weight and BMI, safety evaluation and deqi evaluation. The central randomization and data collection will be conducted by an electronic data management system.

02

Conditions studied

  • Asymptomatic Hyperuricemia

Browse trials for

Keywords

  • Manual Acupuncture
  • Asymptomatic Hyperuricemia
  • Serum Uric Acid
  • Efficacy
  • Safety
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosed as hyperuricemia; and
  • Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and
  • Without history of gouty arthritis; and
  • Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and
  • 18.5kg/m2≤BMI≤30.0kg/ m2; and
  • Able to signing a informed consent.

Exclusion criteria

Exclusion Criteria:

  • Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and
  • Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and
  • Patients have history of gouty arthritis; and
  • Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and
  • Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and
  • Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and
  • Pregnant women; and
  • Unwilling to accept acupuncture treatment; and
  • Illiterate, or patients unable to sign informed consent; and
  • The completion rate of baseline screening data is ≤80%.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Verum acupuncture (VA)

    Participants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.

    Device: verum acupuncture · Behavioral: health education

  • Sham comparator
    Sham acupuncture (SA)

    Participants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.

    Behavioral: health education · Device: sham acupuncture

Interventions

  • Deviceverum acupuncture

    The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.

  • Behavioralhealth education

    According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.

  • Devicesham acupuncture

    We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.

05

What researchers measure

Primary outcomes

  1. Changes in the mean level of serum uric acid from baseline.

    The changes in the mean level of serum uric acid at 8 weeks after randomization compared to baseline

    Time frame: At baseline, and at 8 weeks after randomization.

Secondary outcomes

  1. Changes in the mean level of serum uric acid from baseline.

    The changes in the mean level of serum uric acid at 4, 12, 16, 20 weeks after randomization compared to baseline

    Time frame: At baseline, at 4, 12, 16, and 20 weeks after randomization.

  2. Effective rate of patients with serum uric acid ≤ 6.0 mg/dL

    The ratio of patients with serum uric acid ≤ 6.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization

    Time frame: 4, 8, 12, 16 and 20 weeks after randomization

  3. Effective rate of patients with serum uric acid ≤ 7.0 mg/dL

    The ratio of patients with serum uric acid ≤ 7.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization

    Time frame: 4, 8, 12, 16 and 20 weeks after randomization

  4. The proportion of patients with acute gouty arthritis

    The proportion of patients with acute gouty arthritis per 4-week cycle after randomization.

    Time frame: Weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

  5. Changes in body weight of patients

    Changes in body weight of patients at 4, 8, 12, 16, and 20 weeks after randomization.

    Time frame: 4, 8, 12, 16 and 20 weeks after randomization

  6. Changes in the dose of intake of acute medication.

    The changes in the dose of intake of acute medication per 4-week cycle after randomization.

    Time frame: Weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

  7. Arrival of qi assessment

    The Chinese Version of the Massachusetts General Hospital Acupuncture Sensation Scale Acupuncture sensations will be measured by the Massachusetts General Hospital (MGH) Acupuncture Sensation Scale (MASS)

    Time frame: Immediately following each session of acupuncture treatment.

  8. Safety evaluation

    Adverse events during the acupuncture process

    Time frame: Immediately following each session of acupuncture treatment.

Other outcomes

  1. 60-item NEO Personality Inventory-Short Form (NEO-FFI)

    Time frame: At baseline only once.

  2. Chinese medicine constitution classification

    Time frame: At baseline only once.

  3. Acupuncture Expectancy Scale

    Time frame: At baseline only once.

  4. Change in Beck Anxiety Inventory(BAI).

    Time frame: At baseline only once.

  5. Change in Beck Depression Inventory II(BDI- II).

    Time frame: At baseline only once.

  6. Change in Patient-Doctor Relationship Questionnaire(PDRQ-9) .

    Time frame: At baseline only once.

  7. Change in Difficult Doctor-Patient Relationship Questionnaire(DDPRQ-10).

    Time frame: At baseline only once.

06

Study locations

1 of 1 sites recruiting
  • Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
07

Registry details

Key details

Study ID
NCT05406830
Lead sponsor
Lingling Yu (103250)
Collaborators
Wuhan Integrated Traditional Chinese and Western Medicine Hospital, Xianning Central Hospital
Responsible party
Lingling Yu (103250) (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Jun 7, 2022
Start date
Jul 13, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Lingling Yu, PhD
Contact
527679774@qq.com
86-13545862185
Shenghao Tu, PhD
principal investigator · Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,430030, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion